|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
SAQUINAVIR COMPETES FOR CYP3A ENZYME RESULTING IN IHBITION OF METABOLISM OF OTHER DRUG & CREATE THE POTENTIAL FOR SERIOUS / LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS OR PROLONGED SEDATION
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
CYP3A INHIBITORS CAN INCREASE THE PLASMA LEVELS OF THE OTHER DRUG
|
RANOLAZINE CAN INCREASE PLASMA CONC OF OTHER DRUG DUE TO INHIBITION OF CYP 450 ENZYME
|
RANOLAZINE CAN INCREASE PLASMA CONC OF OTHER DRUG DUE TO INHIBITION OF CYP 450 ENZYME
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
MACROLIDES LIKE ERYTHROMYCIN & OTHER RELATED DRUGS MAY INCREASE ITS PLASMA CONCENTRATION DUE TO REDUCED CLEARANCE
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
NELFINAVIR MAY INCREASE THE DRUG LEVELS TO TOXIC LIMITS DUE TO DECREASED METABOLISM
|
SIMVASTATIN PLASMA LEVELS ARE INCREASED
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|